Reviewer's report

Title: The Effects of Two Vitamin D Regimens on Ulcerative Colitis Activity Index, Quality of Life and Oxidant/Anti-Oxidant Status

Version: 2 Date: 03 Feb 2019

Reviewer: Giorgia Burrelli Scotti

Reviewer's report:

There is no strict relationship between intestinal vitamin D absorption and the vitamin D status in patients, there are other causes could explain the hypovitaminosis D in IBD patients: first of all low sunlight exposure, but also inflammation (that causes conversion of 25(OH) D to 1,25(OH)2D in the intestine, not malabsorption). 1,2 So you can't write malabsorption due to inflammation in the first line.


You should not report the mean dose/die of azathioprine, steroids, or mesalamine, but the percentage of patients taking azathioprine and steroids in that period (12 weeks). For example, in low and high dose group …% and …% respectively were taking azathioprine +/- steroids… (p value).

You should write in limitations the absence of healthy people as controls and the dosage of systemic phlogosis markers (sccai is subjective).

The extension of the disease should be reported (proctitis, left or total colitis)

I appreciate a lot the 2 x2 table with p values within and between groups in table n 2 and 3. It should be done also for table 4 and 5. These last are not understandable.

Ibuprofen not IBOPROFEN
Level of interest
Please indicate how interesting you found the manuscript:

An article whose findings are important to those with closely related research interests

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal